Galapagos (GLPG) Q4 2025 earnings review
A €3 Billion Cash Shell: Accounting Illusions Mask Pipeline Capitulation
Galapagos is no longer an R&D biotech; it is a €3 billion cash shell searching for a purpose. Full-year 2025 Net Income skyrocketed to €320.9 million, but this is a pure accounting illusion. The profit stems entirely from a €1.07 billion non-cash release of deferred income after the company abandoned its drug discovery platform and Gilead collaboration obligations. In reality, the company completely capitulated on its pipeline, recorded €399.8 million in restructuring and impairment charges, and initiated a wind-down of its entire cell therapy and small molecule units. The future rests solely on a new management team using the remaining €3.0 billion war chest for M&A, aiming to shrink the workforce to just 35-40 employees to achieve cash flow neutrality by late 2026.
🐂 Bull Case
The company sits on €3.0 billion in cash and investments (roughly €46 per share). Management's sole mandate is to deploy this capital into clinically derisked, late-stage business development (BD) assets, free from legacy pipeline drag.
By ruthlessly slashing the organization to just 35-40 employees and terminating internal R&D, structural cash burn is reversing. Backed by ~€100 million in annual interest income and Jyseleca royalties, management expects to be cash flow neutral to positive by the end of 2026.
🐻 Bear Case
The €228.1 million impairment of the cell therapy business marks the death of Galapagos's internal R&D. Investors are now entirely dependent on an unproven BD team to buy innovation in an overheated biotech M&A market.
The final legacy asset, GLPG3667 (TYK2 inhibitor), missed statistical significance on its primary endpoint in the Phase 2 SLE trial, severely weakening the narrative for a lucrative out-licensing deal.
⚖️ Verdict: ⚪
Neutral. The underlying operations are a disaster, evidenced by the complete write-off of the R&D pipeline. However, a €3 billion cash balance trading at a discount provides a hard floor. The grade reflects optionality, not operational excellence.
Key Themes
The Accounting Illusion: Profitability is a Mirage
Galapagos reported a stunning 304% YoY revenue surge to €1.11 billion and an operating profit of €295.1 million. This contradicts the fundamental reality of the business. The revenue is purely a non-cash paper gain—the release of €1.07 billion in deferred liability because Galapagos abandoned its drug discovery commitments to Gilead. Real operational cash burn was €189.1 million. Investors must strip out this accounting noise; the core R&D engine is dead, and the profit is a ghost.
Aggressive Treasury Shift to U.S. Dollars (Macro)
Management took decisive macro action by transitioning 72% of its €3.0 billion cash pile into U.S. dollars. This explicitly captures higher U.S. interest rates (~4% vs ~2% for EUR), generating €103 million in fair value and interest gains in 2025. It also structurally aligns the balance sheet with expected U.S.-centric acquisition targets, mitigating future FX friction during dealmaking.
GLPG3667 (TYK2) Misses in SLE
The company's last remaining clinical asset, GLPG3667, delivered mixed Phase 2 results. While it hit the primary endpoint in Dermatomyositis (DM), it failed to reach statistical significance on the primary dose-response endpoint (SRI-4) in Systemic Lupus Erythematosus (SLE) at Week 32. Management is attempting to out-license the asset, but this miss significantly damages their negotiating leverage and lowers the probability of a high-value partnership.
Drastic Headcount Cuts to Drive Margin Reversal
The primary driver for margin and cash flow improvement is extreme cost rationalization. Management is shrinking the company to a skeleton crew of 35-40 employees by the end of 2026. This complete unwinding of the R&D and cell therapy infrastructure is designed to reverse the cash burn and allow baseline revenues (interest and royalties) to fund the BD strategy indefinitely.
Gilead 'Value Leakage' Overhang
As Galapagos pivots to buying external assets, the existing Option, License and Collaboration Agreement (OLCA) with Gilead remains a structural hurdle. The agreement gives Gilead opt-in rights to U.S. assets for a fixed $150 million. Management admitted this creates 'too much value leakage' and will require case-by-case renegotiation with Gilead for future deals, adding complexity and time risk to M&A execution.
Other KPIs
Decelerating significantly from €374.0 million in FY24. This non-IFRS metric strips out the accounting noise of the Gilead revenue release and FX swings, showing the true underlying cash consumption of the business as it winds down legacy operations.
Accelerating by 37% YoY. This is counterintuitive for a company shutting down R&D, but it reflects massive one-time hits: €72.8 million in elevated subcontracting costs primarily to terminate existing collaboration programs early, plus significant severance packages.
Guidance
Decelerating. The midpoint of €2.81 billion implies a sequential drop of roughly 6.3% from the €3.0 billion held at the end of FY25. This assumes no major BD acquisitions are made and covers the final wave of restructuring costs.
Decelerating. This is a €25 million reduction from the prior guidance range of €150-€200 million, indicating management is executing the wind-down slightly more efficiently than initially feared. It remains a heavy one-time cash drag.
Reversing. The company expects to halt its cash bleed by late 2026. This explicitly excludes BD activities and FX fluctuations, relying on a drastically reduced cost base (35-40 employees) covered by interest income and legacy Jyseleca royalties.
Key Questions
M&A Urgency vs Valuation Discipline
With the market clearly valuing the company at a discount to its €3B cash pile, how long is the Board willing to wait for the 'perfect' BD deal before considering a special dividend or massive share buyback to unlock trapped value?
Gilead OLCA Renegotiation
You mentioned the need to renegotiate Gilead's $150M U.S. opt-in rights on a deal-by-deal basis to prevent value leakage. Have you established a standardized framework with Gilead for this, or will every potential acquisition require a bespoke, protracted three-way negotiation?
GLPG3667 Path Forward
Given the failure to reach statistical significance on the primary SLE endpoint, how realistic is a lucrative out-licensing deal for GLPG3667? Are you prepared to fully abandon the asset if partner terms are highly unfavorable, rather than spending the guided €40M in 2026?